RxDoctor Payments Data

Matthew Woodward, MD

Neurology · Pittsburgh, PANPI 1114423274

Payments from drug & device makers

$29,051in general payments, 2019–2025

Across 76 payments — averaging $382.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$11K
  • Abbott$8K
  • Boston Scientific$8K
  • Ipsen Biopharmaceuticals, Inc$700
  • Merz Pharmaceuticals, LLC$324
  • Neurocrine Biosciences, Inc.$291
  • plus $934 from 12 others

What the payments were for

  • Speaking & faculty fees$120%
  • Grants$24,25083%
  • Travel & lodging$1,7876%
  • Food & beverage$3,00210%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,051 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$30,771
Medicare patients
150
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$85,816
RytaryCarbidopa/Levodopa18$32,001
Entacapone11$6,504
Carbidopa-LevodopaCarbidopa/Levodopa151$5,664
Rasagiline Mesylate12$4,686
Carbidopa-Levodopa ErCarbidopa/Levodopa51$2,246
Selegiline Hcl14$1,776
Gabapentin33$1,627
Baclofen21$858
Primidone14$708
Clonazepam15$503
Propranolol Hcl19$356
Donepezil Hcl25$345
Propranolol Hcl ErPropranolol Hcl11$234
Pregabalin14$197

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$291$85,81611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →